Oppenheimer Assumes Ionis Pharmaceuticals (IONS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Price: $40.42 -1.99%
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Oppenheimer analyst Justin Kim assumes coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Outperform rating and a price target of $59.00.
For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.
Shares of Ionis Pharmaceuticals closed at $39.31 yesterday.
You May Also Be Interested In
- Freedom Broker Starts MNTN Inc (MNTN) at Buy
- Ionis to hold third quarter 2026 financial results webcast
- Evercore ISI Starts TRex Bio (TRXB) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
